IDM Pharma Reports 2008 Financi...(ion in the prior year period. SG&A ...)

Date:3/31/2009

ion in the prior year period. SG&A expenses decreased to $10.1 million for the year ended December 31, 2008 from $12.6 million for the year ended December 31, 2007. The higher expenses for the full year 2007 included $0.5 million in fees to an investment advisor in relation to the $12.9 million private equity financing completed in February 2007, $0.8 million associated with cash severance benefits for our former chief executive officer and $0.9 million in higher spending for finance-related consultants, offset by $0.3 million in accrued restoration costs for our Irvine, California facility. Expenses for the 2008 period were also lower due to $0.5 million in savings from the closing of our Paris, France office.

Restructuring expenses were $3.5 million for the year ended December 31, 2008, which was for the closing of our Paris, France office following notification of sanofi-aventis' decision in December 2007 to terminate its participation in the UVIDEM development program. The $3.5 million includes $3.2 million of severance benefits and $0.6 million of shutdown costs, offset by $0.3 million of proceeds from the sale of fixed assets.

Interest income decreased to $0.1 million for the three months ended December 31, 2008 from $0.4 million in the prior year period. Interest income decreased to $0.7 million for the year ended December 31, 2008 from $1.1 million in 2007. Higher interest income in 2007 was primarily the result of higher cash investment balances due to the February and June 2007 financings.

Interest expense related to warrants for the quarter ended December 31, 2008 was a negative expense of $1.6 million compared with a negative expense of $1.1 million in the quarter ended December 31, 2007. Interest expense for the year ended December 31, 2008 was $3.1 million compared to a negative expense of $3.9 million for the year ended December 31, 2007. The interest expense in both the quarter and
'/>"/>

SOURCE IDM Pharma, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
2. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
3. Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio
4. VIA Pharmaceuticals Complies With NASDAQ Rules
5. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
9. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
10. Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results